Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(13 years from now) | |
US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(18 years from now) | |
US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Aug 30, 2024 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 18 May, 2015
Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(7 years from now) |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); Dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(4 years from now) | |
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(1 year, 6 months from now) | |
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(2 years from now) |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2014
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(4 years from now) | |
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(1 year, 6 months from now) | |
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(2 years from now) |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(4 years from now) | |
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(2 years from now) | |
US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
Market Authorisation Date: 29 March, 2013
Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; Treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; Treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6806256 | JANSSEN PHARMS | Taste masked liquid pharmaceutical compositions |
Feb, 2022
(11 months ago) | |
US6806256
(Pediatric) | JANSSEN PHARMS | Taste masked liquid pharmaceutical compositions |
Aug, 2022
(5 months ago) |
Drugs and Companies using LEVOFLOXACIN ingredient
Market Authorisation Date: 21 October, 2004
Treatment: NA
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE43728 | JANSSEN PHARMS | Thiazolidin-4-one derivatives |
Nov, 2024
(1 year, 9 months from now) | |
US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9000018 | JANSSEN PHARMS | Thiazolidin-4-one-derivatives |
Nov, 2024
(1 year, 9 months from now) | |
US8273779 | JANSSEN PHARMS | Thiazolidin 4-one derivatives |
Dec, 2025
(2 years from now) | |
US10220023 | JANSSEN PHARMS | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9592207 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2027
(4 years from now) | |
US8785500 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2033
(10 years from now) | |
US11446260 | JANSSEN PHARMS | Pharmaceutical composition of S-ketamine hydrochloride |
Mar, 2034
(11 years from now) | |
US11311500 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(12 years from now) | |
US10869844 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(12 years from now) | |
US11173134 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 5, 2024 |
New Indication (I) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; Treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks
Dosage: SPRAY;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(1 year, 6 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(1 year, 9 months from now) | |
US7157456
(Pediatric) | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(2 years from now) | |
US9415053
(Pediatric) | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
May, 2025
(2 years from now) | |
US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(11 years from now) | |
US9539218
(Pediatric) | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(11 years from now) | |
US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(16 years from now) | |
US10828310
(Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Aug 23, 2024 |
M | Mar 10, 2023 |
Pediatric Exclusivity (PED) | Apr 11, 2023 |
Drugs and Companies using RIVAROXABAN ingredient
Market Authorisation Date: 01 July, 2011
Treatment: Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Treatment of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cv death, mi, and stroke) in chronic cad or pad; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding; Prophylaxis of thromboembolic diseases in pediatric patients aged 2 years and older with congenital heart disease who have undergone the fontan procedure and a body weight of >=50 kg; Treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of 30 kg to 49.9 kg after at least 5 days of initial parenteral anticoagulant treatment; Reduction in the risk of recurrence of deep vein thrombosis (dvt) and/or pulmonary embolism (pe) in patients at continued risk for recurrent dvt and/or after completion of initial treatment lasting at least 6 months; Prophylaxis of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cardiovascular death, myocardial infarction and stroke) in patients with cad; Reduction of risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of vascular etiology) in patients with pad; Treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of >=50 kg after at least 5 days of initial parenteral anticoagulant treatment; Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; After completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; Prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; Reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic